How should companies talk about alcohol risk?

U.S. regulators consider new alcohol labels, but health advocates want even more

August 12, 2024 Check out STAT+

Sponsored By

Multidisciplinary Association for Psychedelic Studies STAT+ | Three MDMA therapy papers retracted over data integrity concerns The journal Psychopharmacology retracted three papers about MDMA therapy, days after the FDA rejected Lykos' application for approval. By Meghana Keshavan Opinion: The FDA should withdraw approval of more than 400 tainted medicines After learning about fraudulent work by a drug testing company in India, the FDA should have taken the drugs off the market. It didn't. By Suzanne Robotti Opinion: Getting to 'Plan B' for psychedelic medicine: Lessons from reproductive health The road to FDA approval of psychedelic medicines may follow the tortuous route's taken by emergency contraception and mifepristone. By Susannah Baruch Keith Srakocic/AP What's in a drink? U.S. regulators consider new alcohol label, but health advocates want even more New rules are coming for nutrition labels on alcoholic beverages. Advocates want stronger health warnings as well. Would they be effective? By Isabella Cueto

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser